Problems of Radiation Medicine and Radiobiology

V. S. Svintsitskiy¹, N. P.Tsip¹, S. V. Nespryadko¹, O. I. Bubliieva¹, O. M. Movchan¹,
M. O. Polukhina²

¹ National Cancer institute, 33/43 Lomonosova Str., Kyiv, 03022, Ukraine
² Bogomolets National Medical University, 13 Tarasa Shevchenka Ave., Kyiv, 01601, Ukraine

RADIATION AND CHEMORADIATION THERAPY FOR I STAGE INTERMEDIATE AND HIGH/INTERMEDIATE ENDOMETRIAL CANCER – DESCRIPTIVE ANALYSIS

Introduction. Endometrial cancer ranks the third place in prevalence among all cancers in Ukraine. The surgical treatment and subsequent adjuvant treatment is planned according to the patient's risk group. The choice of radiation therapy and the need to add chemotherapy determines the level of recurrence-free survival.
Objective. The aim of the study was to analyze the database of treated patients in National Cancer Institute, with I stage endometrial cancer intermediate and high-intermediate group; determination of the most frequent choice of radiation treatment in accordance with the risk group of patients with a hysterectomy with salpingo-oophorectomy for further observation and evaluation of diseasefree survival.
Materials and methods. Retrospective was analysed 245 patients with high and intermediate risk groups with stage I endometrial cancer. The exclusion criteria were: low-risk patients, stages II–IV and non-endometrioid histological variant.
Results. According to the analysis, there were 122/245 (49.8 %) patients of high risk group, 123/245 (50.2 %) of intermediate risk group. High-risk patients underwent external beam therapy and brychytherapy, supplemented by chemotherapy in 5.8 % of cases (7 patients), brachytherapy with external beam therapy was performed in 58.2 % of cases (71 patients), brachytherapy – in 8.1 % of cases (10 patients), external beam therapy was performed in 27.9 % cases. Intermediate and high-intermediate risk patients were distributed as follows: brachytherapy was performed in 41.5 % of cases (51 patients), brachytherapy with external beam therapy – 54.5 % (67 patients), external beam therapy was performed in 5 patients.
Conclusion. Brachytherapy is available for patients with intermediate risk endometrial cancer and external beam therapy with possible addition of brachytherapy is recommended for high-intermediate and high-risk groups, especially in patients with lymphatic vascular involvement. All patients are monitored for further assessment of recurrence-free survival.
Key words: endometrial cancer, lymphadenectomy, external beam therapy, chemo- and radiotherapy.

Problems of Radiation Medicine and Radiobiology.
2021;26:554-561. doi: 10.33145/2304-8336-2021-26-554-561

full text

1. [The charechteristics of treatment malignant tumors depanding of staging]. Cancer in Ukraine, 2018–2019. Morbidity, mortality, indicators of the oncology service. Bulletin of the National Cancer Registry of Ukraine. 2020;(21):82-105. Ukrainian.
2. Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv. 2021 Feb;478(2):153-190. https://doi.org/10.1007/s00428-020-03007-z.
3. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125-36. doi: 10.1016/S0140-6736(08)61766-3.
4. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-1716. doi: 10.1093/jnci/djn397.
5. Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Marton A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16-41. doi: 10.1093/annonc/mdv484.
6. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. / Creutzberg CL, van Putten WL, Koper PC et al. Lancet. 2000;355(9213):1404–1411. doi: 10.1016/s0140-6736(00)02139-5. PMID: 10791524.
7. Creutzberg CL, Nout RA, Lybeert MLM, Warlam-Rodenhuis CC, Jobsen JJ, Mens JWM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for Endometrial Carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e631-e638. doi: 10.1016/j.ijrobp.2011.04.013.
8. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816-823. doi: 10.1016/S0140-6736(09)62163-2.
9. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X.
10. Randall ME, Filiaci V, McMeekin DS, Von Gruenigen V, Huang H, Yashar CM, et al. Phase III trial: Adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/ carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol. 2019;37(21):1810-1818. doi: 10.1200/JCO.18.01575.
11. Van Den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, Van Der Steen-Banasik EM, Westerveld GH, et al. PORTEC-4a: International randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020;30(12):2002-2007. doi: 10.1136/ijgc-2020-001929.